BioTime (BTX) Posts Q3 EPS of 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Asterias Biotherapeutics to Report Third Quarter Results on November 14, 2016
November 4, 2016 7:00 AM EDTFREMONT, Calif., Nov. 4, 2016 /PRNewswire/ --Â Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third quarter financial results and provide an update on clinical progress on Monday, November 14, 2016 after the close of the U.S. financial markets.
The Company will host a conference call and webcast on November 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Company management will be joined by Shekar N. Kurpad, MD, PhD, Professor of Neurosurgery, Director, Spinal Cord Injury Center Medical College of... More
BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
November 3, 2016 4:01 PM EDTInitial data from OpRegen® trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia® trial run-in patients suggest volumetric improvements are sustained at least 12 months
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today reported financial results for the third quarter ended September 30, 2016, and recent therapeutic program progress.
Through the quarter, we continued... More
